Oncology/Hematology Market Research Reports & Industry Analysis
Oncology/Hematology Industry Research & Market Reports
-
Genomics in Cancer Care
... 2030, growing at a CAGR of 16.7% over the analysis period 2024-2030. Genomics Instruments, one of the segments analyzed in the report, is expected to record a 15.4% CAGR and reach US$25.0 Billion by the ... Read More
-
Urothelial Cancer Drugs
... at a CAGR of 20.7% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 20.3% CAGR and reach US$13.3 Billion by the end of the ... Read More
-
Oncology Based In-Vivo CRO
... 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Solid Tumors Indication, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$1.2 Billion by ... Read More
-
Cancer Immunotherapy
... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More
-
Cancer Stem Cells
... at a CAGR of 8.5% over the analysis period 2024-2030. Stem Cell-based Cancer Therapy, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.3 Billion by the ... Read More
-
Interventional Oncology Devices
... at a CAGR of 6.4% over the analysis period 2024-2030. Embolization Devices, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$2.4 Billion by the end of ... Read More
-
Chronic Myelogenous Leukemia Treatment
... 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Disease Specific Treatment, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$3.4 Billion by ... Read More
-
Hematology Testing Products
... at a CAGR of 4.4% over the analysis period 2024-2030. Hematology Testing Instruments & Software, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$9.8 Billion by ... Read More
-
Multiple Myeloma Therapeutics
... at a CAGR of 14.5% over the analysis period 2024-2030. Chemotherapy & Other Drugs, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$37.6 Billion by the ... Read More
-
Prostate Cancer Therapeutics
... at a CAGR of 6.6% over the analysis period 2024-2030. Hormone Therapy, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$21.0 Billion by the end of ... Read More
-
Tumor / Cancer Markers
... 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 10.4% CAGR The Tumor / Cancer Markers market ... Read More
-
Cancer / Tumor Profiling
... 2030, growing at a CAGR of 9.9% over the analysis period 2024-2030. Immunoassays Technology, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$6.7 Billion by the ... Read More
-
Cancer Supportive Care
... at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
-
Leukemia Therapeutics
... CAGR of 5.6% over the analysis period 2024-2030. Chronic Myeloid Leukemia Therapeutics, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$9.1 Billion by the end of ... Read More
-
Non-Melanoma Skin Cancer
... at a CAGR of 4.4% over the analysis period 2024-2030. Basal Cell Carcinoma (BCC) Indication, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$835.6 Million by ... Read More
-
Oncology Information Systems
... at a CAGR of 6.2% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$5.5 Billion by the end of ... Read More
-
Colorectal Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Breast Cancer Therapeutics
... at a CAGR of 12.3% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$74.9 Billion by the end of ... Read More
-
Basal Cell Carcinoma Treatment
... 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Surgery Treatment, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$7.6 Billion by the ... Read More
-
Cervical Cancer Treatment
... at a CAGR of 6.0% over the analysis period 2024-2030. Squamous Cell Carcinoma (SCC) Treatment, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$9.1 Billion by ... Read More
-
Breast Cancer Liquid Biopsy
... 2030, growing at a CAGR of 21.9% over the analysis period 2024-2030. Liquid Biopsy Reagent Kits, one of the segments analyzed in the report, is expected to record a 22.4% CAGR and reach US$819.3 Million ... Read More
-
Cancer Registry Software
... at a CAGR of 9.6% over the analysis period 2024-2030. Standalone Software, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$116.6 Million by the end of ... Read More
-
Biosimulation Market by Offering (Module, Integrated Platform), Application (Disease Modeling, PBPK, PKPD, Trial Simulation, Manufacturing & Supply chain: planning & forecasting), Indication (Cancer, CNS, CVS), End User, & Region - Global Forecast to 2029
... the drug development process has been one of the major drivers in the adoption of biosimulation tools. These tools predict how the drugs will behave inside the human body, potentially minimizing the requirements of extensive ... Read More
-
Gynecological Cancer Drugs
... at a CAGR of 5.1% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$12.1 Billion by the end of ... Read More
Research Assistance
